Plasma cell myeloma refractory
RecruitingStudy Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide
Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide
- Disease:Plasma cell myeloma refractory
- Substances:CarfilzomibCyclophosphamide+7
Hungary- Participants:18–64 years · 65+ years
- Substances:Carfilzomib
- Sponsor:Celgene Corp.














